Vancouver-based SaNOtize Raises $24 Million in Series-B Financing to Advance Its Nitric Oxide-Based Therapeutics. Vancouver, BC, August 26, 2022 Vancouver-based SaNOtize Research & Development Corp., an anti-infective-focused therapeutics company, announced an oversubscribed $24 million Series-B funding round to advance its nitric oxide-based therapeutics pipeline.